Champions Oncology Statistics
Share Statistics
Champions Oncology has 13.59M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 13.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.88M |
| Failed to Deliver (FTD) Shares | 955 |
| FTD / Avg. Volume | 3.84% |
Short Selling Information
The latest short interest is 189.50K, so 1.39% of the outstanding shares have been sold short.
| Short Interest | 189.50K |
| Short % of Shares Out | 1.39% |
| Short % of Float | 3.22% |
| Short Ratio (days to cover) | 16.3 |
Valuation Ratios
The PE ratio is -9.03 and the forward PE ratio is 24.42.
| PE Ratio | -9.03 |
| Forward PE | 24.42 |
| PS Ratio | 1.31 |
| Forward PS | 1.6 |
| PB Ratio | -34.53 |
| P/FCF Ratio | -9.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Champions Oncology Inc. has an Enterprise Value (EV) of 64.29M.
| EV / Earnings | -8.84 |
| EV / Sales | 1.28 |
| EV / EBITDA | -12.72 |
| EV / EBIT | -8.74 |
| EV / FCF | -9.22 |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of -0.7.
| Current Ratio | 0.63 |
| Quick Ratio | 0.63 |
| Debt / Equity | -0.7 |
| Total Debt / Capitalization | -236.22 |
| Cash Flow / Debt | -4.59 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 3.82% and return on capital (ROIC) is -132.51%.
| Return on Equity (ROE) | 3.82% |
| Return on Assets (ROA) | -0.28% |
| Return on Capital (ROIC) | -132.51% |
| Revenue Per Employee | 238.83K |
| Profits Per Employee | -34.65K |
| Employee Count | 210 |
| Asset Turnover | 1.92 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -32.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 34.27% in the last 52 weeks. The beta is 0.49, so Champions Oncology 's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | 34.27% |
| 50-Day Moving Average | 4.48 |
| 200-Day Moving Average | 4.78 |
| Relative Strength Index (RSI) | 71.06 |
| Average Volume (20 Days) | 24.90K |
Income Statement
In the last 12 months, Champions Oncology had revenue of $50.16M and earned -$7.28M in profits. Earnings per share was $-0.54.
| Revenue | 50.16M |
| Gross Profit | 20.75M |
| Operating Income | -7.36M |
| Net Income | -7.28M |
| EBITDA | -5.05M |
| EBIT | -7.36M |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
The company has $2.62M in cash and $7.43M in debt, giving a net cash position of -$4.81M.
| Cash & Cash Equivalents | 2.62M |
| Total Debt | 7.43M |
| Net Cash | -4.81M |
| Retained Earnings | -84.59M |
| Total Assets | 25.24M |
| Working Capital | -4.78M |
Cash Flow
In the last 12 months, operating cash flow was -$6.14M and capital expenditures -$836.00K, giving a free cash flow of -$6.97M.
| Operating Cash Flow | -6.14M |
| Capital Expenditures | -836.00K |
| Free Cash Flow | -6.97M |
| FCF Per Share | -0.51 |
Margins
Gross margin is 41.38%, with operating and profit margins of -14.67% and -14.51%.
| Gross Margin | 41.38% |
| Operating Margin | -14.67% |
| Pretax Margin | -14.57% |
| Profit Margin | -14.51% |
| EBITDA Margin | -10.08% |
| EBIT Margin | -14.67% |
| FCF Margin | -13.9% |
Dividends & Yields
CSBR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.72% |
| FCF Yield | -8.28% |
Analyst Forecast
The average price target for CSBR is $8, which is 29.2% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8 |
| Price Target Difference | 29.2% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 12, 2015. It was a backward split with a ratio of 1:12.
| Last Split Date | Aug 12, 2015 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 2.37 |
| Piotroski F-Score | 2 |